Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer

Zhao, Ren; Zhang, Cai; Li, Sheng; Cheng, Yanan; Gao, Hua; Liu, Fang; Wu, Shiyang; Liu, Suyan; Dong, Yan; Zheng, Lei; Zhang, Wenbin; Wu, Xiaojun; Yao, Xueqing

doi:10.18632/oncotarget.14065

Cited by 93 publications

(82 citation statements)

References 44 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…In the present study, we used the CanPatrol technique to count and characterize CTCs in a single test . The CanPatrol technique characterizes and classifies CTCs into epithelial, biophenotypic and mesenchymal phenotypes . Compared with the CellSearch platform, which uses anti‐EpCAM‐coated magnetic beads to capture CTCs, the CanPatrol technique uses an unbiased CTC isolation method that allows the isolation of CTCs that do not detectably express epithelial markers .…”

Section: Discussionmentioning

confidence: 99%

“…Counting and characterization of CTCs were performed using the CanPatrol CTC technique (SurExam, Guangzhou, China), as described in detail in previous studies [10][11][12][13][14][15][16]. Specifically, the CanPatrol CTC technique employs a filtration system comprising a filtration tube containing a calibrated membrane (8-lm-diameter pores; SurExam), a manifold vacuum plate with valve settings (SurExam), an E-Z 96 vacuum manifold (Omega, Norcross, GA, USA), and a vacuum pump (Auto Science, Tianjin, China).…”

Section: Isolation and Characterization Of Circulating Tumour Cellsmentioning

confidence: 99%

See 2 more Smart Citations

Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration‐sensitive prostate cancer

Yang

Kong

et al. 2019

BJU International

View full text Add to dashboard Cite

Objectives To identify biomarkers that predict the response to standard androgen deprivation therapy (ADT) of patients newly diagnosed with metastatic castration‐sensitive prostate cancer (CSPC) in order to improve therapeutic decision‐making, and to investigate whether the characterization of baseline circulating tumour cells (CTCs) would predict the effective period of standard ADT. Materials and Methods The study included 108 patients newly diagnosed with high‐volume metastatic CSPC. Enumeration and characterization of patients’ baseline CTCs (CTCs+ and CTCs−, indicating detectable and undetectable CTCs, respectively) were performed using the CanPatrol technique, which detects markers of the epithelial to mesenchymal transition (EMT) in CTCs, and classifies CTCs into epithelial, biophenotypic and mesenchymal phenotypes. Results After a median follow‐up of 24 months, 90 patients (83.3%) progressed to castration‐resistant prostate cancer (CRPC), 93 patients (86.1%) had detectable CTCs, and the median number of CTCs was 4. The rate of progression to CRPC was significantly higher for patients with mesenchymal CTCs+ than for patients with CTCs+/mesenchymal CTCs− and CTCs− (93.1% vs 71.4% and 73.3%; P = 0.013). The median time to CRPC for patients with mesenchymal CTCs+ was significantly shorter than for those with CTCs+/mesenchymal CTCs− and CTCs− (10.5 months vs 18.0 and 14.0 months; P = 0.003). Multivariate Cox regression analysis suggested that the CTC phenotype was the only independent prognostic factor influencing the progression of disease from CSPC to CRPC. Conclusions Characterization of baseline CTCs according to the EMT phenotype predicted the effective period of standard ADT for patients newly diagnosed with metastatic CSPC. These findings are important for counselling patients and designing clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Isolation and Characterization Of Circulating Tumour Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration‐sensitive prostate cancer

Yang

Kong

et al. 2019

BJU International

View full text Add to dashboard Cite

show abstract

“…CTCs are released into the bloodstream during metastatic spread of the cancer through blood and are present as single cells or clusters [13]. They have been detected in various metastatic carcinomas including lung [14], breast [15,16], prostate [17], and colorectal cancer [18] but are extremely rare in healthy subjects and patients with nonmalignant diseases [19]. Even in patients with metastatic cancer, they occur on average at a frequency of 1 in 100 million cells and are mixed with approximately 10 million leukocytes and 5 billion erythrocytes per 1 ml blood [20].…”

Section: Circulating Tumor Cells (Ctcs)mentioning

confidence: 99%

Liquid biopsy - emergence of a new era in personalized cancer care

2018

View full text Add to dashboard Cite

The most successful treatment for cancer involves identifying druggable, biological markers for targeted therapy. In the clinical setting, surgical removal of tumors is the only procedure for identifying such targetable molecules. Shed from tumor cells, these markers are also present in circulating blood, albeit in very negligible amounts. Liquid biopsy is a procedure performed on a blood sample to look for such circulating cancer markers cells or pieces of nucleic acid from the tumor. The procedure shows promise in revolutionizing personalized cancer treatments. Here we briefly review the technique, characterization, and its utilization in clinics.

show abstract

“…In endometrial cancer, CTCs were also found to express CD44 and ALDH (another cancer stemness marker), and in an orthotopic mouse model of colon cancer, CTCs were shown to have stem cell properties with significantly upregulated stem cell markers of DLG7 and BMI1 . It was also reported that CTCs and CSCs share a common feature in the process of epithelial‐mesenchymal transition (EMT), a prerequisite for CTC migration and CSC transformation . However, the detailed relationship and mechanism of how CTCs derive from CSCs and how CSCs promote CTC or CTC cluster formation and transport have yet been elucidated.…”

Section: Introductionmentioning

confidence: 99%

Cancer stemness contributes to cluster formation of colon cancer cells and high metastatic potentials

Kapeleris

Zou

Yan

et al. 2020

Clin Exp Pharma Physio

View full text Add to dashboard Cite

The ability of cancer cells to form clusters is a characteristic feature in the development of metastatic tumours with drug resistance. Several studies demonstrated that clusters of circulating tumour cells (CTCs) have a greater metastatic potential to establish new tumours at secondary sites than single CTCs. However, the mechanism of cluster formation is not well understood. In this study, we investigated whether cancer stemness would contribute to cluster formation. We used a tumour sphere culture method to enrich cancer stem cells (CSCs) from colon cancer cells and found that during the second generation of sphere culture, clusters (between 3 and 5 cells) formed within the first 24 hours, whereas the rest remained as single cells. The clusters were analysed for stemness and metastatic potential, including gene expressions for cancer stemness (CD133 and Lgr5), epithelial‐mesenchymal transition (E‐cadherin and TGF‐β 1‐3) and hypoxia‐induced factors (HIF‐1α and HIF‐2α). The results showed that the clusters expressed higher levels of these genes and colon CSC surface markers (including CD24, CD44 and CD133) than the single cells. Among these markers, CD24 seemed the major contributor linking the cells into the clusters. These clusters also showed a stronger ability to both form colonies and migrate. Our data collectively suggest that colon cancer stemness contributes to cluster formation and that clustered cells exhibit a great metastatic potential. Our study thus provides a method to study the CTC clusters and derive insight into oncogenesis and metastasis.

show abstract

Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer

Abstract: ABSTRACT

Cited by 93 publications

References 44 publications

Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration‐sensitive prostate cancer

Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration‐sensitive prostate cancer

Liquid biopsy - emergence of a new era in personalized cancer care

Cancer stemness contributes to cluster formation of colon cancer cells and high metastatic potentials

Contact Info

Product

Resources

About